*********************************
There is now a CONTENT FREEZE for Mercury while we switch to a new platform. It began on Friday, March 10 at 6pm and will end on Wednesday, March 15 at noon. No new content can be created during this time, but all material in the system as of the beginning of the freeze will be migrated to the new platform, including users and groups. Functionally the new site is identical to the old one. webteam@gatech.edu
*********************************
Novel Technology Development Grants from the National Cancer Institute
Tony Dickherber, Ph.D.
Program Director
Innovative Molecular Analysis Technologies (IMAT) Program
Center for Strategic Scientific Initiatives
National Cancer Institute
The Innovative Molecular Analysis Technologies (IMAT) program is one of the National Cancer Institute’s longest-standing programs and specifically targets the need for potentially disruptive technology development to advance cancer research. This program employs unique solicitation and review mechanisms better suited to appreciating the longer term potential of transformative technologies and designed to be more tolerant of the substantial risks often associated with pursuing such research. The program has funding opportunities available through 2017, with an $11M budget specifically reserved for supporting meritorious applications. The degree to which these solicitations and associated review is distinct from other NIH funding opportunities can be surprising for investigators with extensive experience with NIH review practices. The unique aspects of both the solicitation and review of applications to this program will be presented, and the diversity of recently-supported research projects will be described to demonstrate the variety and high level of innovation evident in the IMAT portfolio of supported research. Recent efforts conducted under the White House Cancer Moonshot Initiative identified a variety of technology gaps and priorities for novel technology development which will also be discussed.
